Analytical Data
-
Gene name
MDM2
- Application
-
Alternative Names
HDMX; hdm2; Mouse Double Minute 2,Human Homolog Of p53-Binding Protein; Oncoprotein Mdm2
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q00987
-
Expression Region
Met1~Pro491
-
Molecular Weight
80kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
MDM2 is an important negative regulator of the p53 tumor suppressor protein, playing a crucial role in the regulation of cell cycle, apoptosis, and the response to DNA damage. Overexpression of MDM2 is frequently observed in various types of cancers, contributing to tumorigenesis by promoting the degradation of p53, thus inhibiting its function in controlling cell growth and inducing apoptosis in response to cellular stress. The study of recombinant MDM2 protein has gained significance in cancer research, as it helps elucidate the molecular mechanisms underlying p53 regulation and provides potential therapeutic targets. Researchers have focused on developing MDM2 inhibitors to restore p53 activity in tumors where MDM2 is overexpressed, representing a promising approach for cancer treatment. Furthermore, recombinant MDM2 proteins are valuable tools for investigating the interaction between MDM2 and p53, helping to identify critical binding sites and regulatory mechanisms. Understanding MDM2’s structure and function through recombinant protein studies may lead to novel strategies for overcoming therapeutic resistance in cancer cells and advancing personalized medicine approaches in oncology.
